Open AccessNexavar®-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012
Author(s) -
Felisa Cilurzo,
Orietta Staltari,
Marinella Patanè,
Michele Ammendola,
Caterina Garaffo,
Eugenio Donato Di Paola
Publication year - 2013
Publication title -
journal of pharmacology and pharmacotherapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.301
H-Index - 34
eISSN - 0976-5018
pISSN - 0976-500X
DOI - 10.4103/0976-500x.120971
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , drug reaction , vomiting , adverse effect , health records , food and drug administration , drug , adverse drug reaction , pharmacology , health care , economics , economic growth
Hepatocellular carcinoma (HCC) remains a major global health problem and Calabria in the south of Italy is not an exception. Sorafenib is the first and only Food and Drug Administration approved drug for the treatment of advanced HCC and it is currently under intensive monitoring by the Health Authorities in Italy Agenzia Italiana del Farmaco. This general report has been developed with the aim of briefly reviewing the data found in the reports of adverse reactions (ADRs) collected in Calabria in 2012 for sorafenib treated patients. Extrapolated data have highlighted some differences between the adverse drug reactions reported in patients younger or older than 70 years and other important differences with the current approved leaflet. Several limitations might be present in data analysis form spontaneous reporting, however, the relevance of reporting ADRs (dermatitis, asthenia, vomiting, etc.) for the early identification of drug related signals has to be underlined.